artemether has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amambua-Ngwa, A; Dugassa, S; Golassa, L; Jaiteh, FK; Oboh, M; Oriero, E; Tadele, G | 1 |
| Chen, J; Huang, X; Li, X; Ma, M; Tao, C; Wu, Z; Xiao, T; Zeng, Q | 1 |
2 other study(ies) available for artemether and Disease Exacerbation
| Article | Year |
|---|---|
Persistence of Residual Submicroscopic P. falciparum Parasitemia following Treatment of Artemether-Lumefantrine in Ethio-Sudan Border, Western Ethiopia.
Topics: Adolescent; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Disease Progression; Ethanolamines; Ethiopia; Fluorenes; Humans; Malaria; Malaria, Falciparum; Parasitemia; Plasmodium falciparum; Sudan; Treatment Outcome | 2022 |
Artemether Attenuates the Progression of Non-small Cell Lung Cancer by Inducing Apoptosis, Cell Cycle Arrest and Promoting Cellular Senescence.
Topics: A549 Cells; Apoptosis; Artemether; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Cyclins; Disease Progression; DNA Damage; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation | 2019 |